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Abstract
Introduction: The aim of this study was to identify clinical variables which may be independently associated with positivity of a cardiac troponin I 
(cTnI) assay in a large population of patients admitted to the emergency department (ED). 
Materials and methods: 3166 subjects, with at least two troponin I tests ordered within 6 hours in the ED, were studied. Patient data were stati-
stically analyzed to identify clinical associations with increased values of Troponin I. 
Results: Although patients with diagnosis of acute coronary syndrome displayed troponin I values significantly higher than those of other groups, 
positivity to troponin I (> 40 ng/L) was also observed in patients with other clinical conditions. In multivariate analysis, age, elevated heart rate and 
electrocardiographyc changes were independently associated with troponin I positivity at admission. In the whole study population troponin I posi-
tivity exhibited high sensitivity and negative predictive value, counterbalanced by low specificity and limited positive predictive value.
Conclusions: Troponin I positivity should be combined with history and clinical evaluation and cautiously interpreted in the ED, especially in pati-
ents exhibiting factors associated with higher troponin I levels such as older age, elevated heart rate or ECG changes.
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The clinical diagnosis of ST-elevation myocardial 
infarction (STEMI) and of non ST-elevation MI 
(NSTEMI), according to the universal definition of 
myocardial infarction (MI), is based on the detec-
tion of a rise and/or fall of cardiac biomarker val-
ues, preferably cardiac troponins (cTn), with at 
least one value above the 99th percentile upper 
reference limit (URL) (1). Guidelines usually recom-
mend that blood samples for the measurement of 
cTn should be drawn on first assessment and re-
peated 3–6 h later (1-3). Patients with suspected 
acute coronary syndrome (ACS) typically present 
to the Emergency Department (ED) within a few 
hours or even minutes after symptom onset (4). 
Therefore, delay of blood sampling may increase 
costs for hospital observation and/or admission, 
whereas early cTn negativity may lead to missing 
some diagnoses of MI.
The new and more (i.e., “highly”) sensitive cTn as-
says can detect myocardial injury substantially ear-
lier than the previous generation of assays (5), due 
to the improved analytical sensitivity. Neverthe-
less, since cTn is a general biomarker of myocardial 
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injury, a variety of different causes of myocardial 
damage such as inflammation (6) pulmonary em-
bolism (7) and heart failure (8) may cause increased 
level of plasma cTn. On the other hand, these as-
says should be regarded as significant step for-
ward for diagnosing patients with stable cardio-
vascular disease and to anticipate their prognosis 
(9). The availability of new, high-sensitivity (HS) cTn 
tests, along with the more extensive use of this 
test in ED as universal “screening for MI”, has re-
markably increased the number of patient testing 
positive for cTn (i.e., cTn value over the 99th percen-
tile of a reference population) (10). The obvious 
consequence is a further increase in the workload 
necessary to rule out ACS in cTn positive patients. 
Emergency physicians have therefore been faced 
with the paradox of increasing efforts to trouble-
shoot the causes of potential positivity of this 
marker due to conditions other than myocardial is-
chemia. The aim of this study was to identify clini-
cal variables which may be independently associ-
ated with positivity of a cTnI assay in a large popu-
lation of patients admitted to the emergency de-
partment (ED).The main novelty of this study re-
sides in providing valuable information about cTnI 
in order to help emergency physicians to appro-
priately use and interpret this test in a day-to-day 
clinical setting of an ED. 
Materials and methods
Subjects
Between April 2012 and March 2013, 33,496 cTnI 
tests were performed in the local hospital labora-
tory, corresponding to 11,470 different patients. A 
total number of 5,596 out of these patients, having 
at least 2 cTnI tests ordered within 6 hours, were 
further selected. Among these patients, 3,188 
were admitted to the ED, and complete clinical 
data were available in 3,166 subjects who were 
hence finally included in the study.
Median basal (t1) and following (t2) cTnI values (ex-
pressed as ng/L, following IFCC recommendations) 
were classified according to ED discharge diagno-
sis. Nevertheless, additional information was ac-
quired in order to perform a statistical analysis in 
the population sample and in specific subgroups, 
as follows:
Electrocardiograms (ECG) obtained at presenta-
tion were retrospectively re-interpreted, by three 
expert physicians, in a blinded fashion as 1) nor-
mal or non-diagnostic: paced rhythm or old left 
bundle-branch block (LBBB), non-specific ST-T 
changes; 2) as suggestive of ACS: ST-segment de-
pression or elevation (≥ 1.0 mm in more than two 
contiguous leads), new onset of LBBB or new T-
wave inversion. 
Chest pain was retrospectively classified as typical 
or atypical by two expert physicians using the fol-
lowing criteria (11,12): typical chest pain was dif-
fuse at the entire chest, localized under sternum or 
epigastric, gradual or waxing and waning onset, 
duration ranging from few minutes to 2 hours, 
spontaneous or provoked by activity, not influ-
enced by respiration or changes in body position, 
described as squeezing, tightness, pressure, con-
striction, crushing, strangling, burning, heartburn, 
fullness in the chest, band-like sensation, knot in 
the center of the chest, lump in throat,  heavy 
weight on chest, toothache. Irradiation to epigas-
trium, shoulders, arms, wrist, neck and throat, low-
er jaw and teeth or interscapular region was in-
stead considered atypical. 
Data were also retrospectively re-evaluated by 
two expert physicians and patients were consid-
ered as “unequivocal ACS” if they were admitted 
to ED with chest pain, with ECG changes sugges-
tive of ACS and with a coronary angiography 
showing stenosis > 70% of lumen diameter of 1 or 
more coronary arteries (13).
The study was planned according to the guide-
lines of the local ethical committee in conformity 
to the principles of the Declaration of Helsinki.
Methods
Blood samples were collected in Becton Dickinson 
Vacutainer Plastic tubes containing lithium hepa-
rin (Vol. 4.5 mL, Ref. 366567) (BD Diagnostics, 
Franklin Lakes, New Jersey, USA). cTnI concentra-
tion was measured with the TnI-Ultra method, on 
ADVIA Centaur®CP platform (Siemens Healthcare 
Diagnostic, Erlangen, Germany). The threshold val-
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ue of this assay, which is the value beyond which 
the concentration of cTnI is considered clinically 
significant and corresponding to the 99th percen-
tile, is 40 ng/L (CV 10%). The TnI test was hence 
classified as “positive” in the presence of values > 
40 ng/L, whereas values equal or lower than this 
threshold were considered as “negative”. 
Statistical analysis
Statistical analyses and graphs were performed by 
SPSS statistical software v. 15.0 (SPSS Inc., Chicago, 
IL, USA) and R software v. 2.15.1 (R Foundation for 
Statistical Computing). Differences between 
groups were estimated by non-parametric Kruskal-
Wallis (with Bonferroni correction for multiple 
comparisons) or Mann-Whitney tests. Differences 
in proportions were estimated by Chi-squared or 
Fisher’s exact test. Confidence intervals (CI) were 
calculated using CIA software v. 2.1.1 (by T Bryant, 
University of Southampton, UK). Distribution of 
basal and subsequent cTnI data, assessed by the 
Kolmogorov–Smirnov and the Shapiro-Wilk tests, 
and visually by histogram and kernel density plot, 
was found to be highly skewed. Predictors for pos-
itive cTnI test (> 40 ng/L) were estimated by uni-
variate and multivariate logistic regression. Sensi-
tivity (Se), specificity (Sp), positive predictive value 
(PPV) and negative predictive value (NPV) to de-
tect “unequivocal ACS” were calculated in the 
whole sample and in three subgroups (see column 
1 in Table 2) and were provided with their 95% 
confidence intervals, according to the efficient-
score method (corrected for continuity).
Results
cTnI values and ED diagnosis
The study population included 3,166 patients, 
1,757 males (55.5%) and 1,409 females (44.5%), 
with a median age of 72 years (interquartile range 
[IQR] 57-82 years, min-max 16-104 years). The pa-
tients were classified in 16 groups according to dis-
charge diagnosis from the ED. Table 1 shows basal 
(time 1: admission) and following (time 2: within 6 
h) cTnI values. Patients with ACS (group 3; N = 303) 
displayed both basal and subsequent cTnI values 
significantly higher than those of other groups 
(Bonferroni correction; group 3 vs. all other groups: 
P < 0.01). 
Table 1 shows also the change of cTnI positivity (% 
of values > 40 ng/L) between the two time points. 
In all groups, but not 8, the rate of cTnI positivity 
increased from time 1 to time 2, with larger in-
crease for groups 1 (from 62.0 to 74.1%), 2 (from 
26.2 to 35.3%) and 3 (from 76.2 to 93.7%). Interest-
ingly, 230 out of 231 positive basal cTnI values in 
group 3 (ACS) were confirmed as positive also at 
time 2.
cTnI and clinical presentation: chest pain and 
admission heart rate
Among all patients admitted to the ED, 1,629 
(51.5%) did not report chest pain, 657 (20.7%) and 
666 (21.0%) respectively reported typical and 
atypical chest pain, whereas 214 (6.8%) reported a 
chest pain that was not classified as typical/atypi-
cal. Patients without chest pain displayed basal 
and subsequent cTnI values significantly higher 
than patients with typical or atypical pain (Bonfer-
roni correction; P < 0.003). 
In the ACS group (N = 303), 73 patients (24.1%) did 
not report chest pain, 131 (43.2%) and 54 (17.8%) 
respectively reported typical and atypical chest 
pain, whereas 45 (14.9%) reported a chest pain 
that was not classified as typical/atypical. In this 
group, no association between chest pain type 
and cTnI positivity at either time point was ob-
served. However, patients without chest pain (N = 
73) showed significantly higher basal cTnI values 
than patients with chest pain (N = 230) (P = 0.022). 
Surprisingly, no difference was found in cTnI values 
of the second time point (P = 0.216).
Patients with elevated admission heart rate (HR > 
100 bpm, 18.1%) displayed significantly higher ba-
sal cTnI values (Bonferroni correction, P < 0.0015) 
and larger prevalence of cTnI positivity (P < 0.001) 
than patients with lower HR. No difference was 
found between patients with admission HR < 60 
bpm (6.1%) and HR between 60 and 100 bpm 
(75.8%).
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ED Diagnosis group
N of patients (%)
cTnI t1
median (IQR),
N of patients (%)
cTnI t2
median (IQR),
N of patients (%)





POS at both times: 151 (59.2)





POS at both times: 54 (24.0)
3







POS at both times: 230 (75.9)





POS at both times: 109 (11.0)
5
Pneumonia, COPD, dyspnoea, respiratory failure, 







POS at both times: 154 (53.1)





POS at both times: 43 (36.8)





POS at both times: 31 (30.4)





POS at both times: 50 (57.5)





POS at both times: 13 (17.3)





POS at both times: 31 (12.3)





POS at both times: 16 (47.1)





POS at both times: 4 (8.3)
13
Gastritis, vomiting, abdominal pain, diarrhea, acute 







POS at both times: 45 (23.8)
Table 1. Median basal (t1) and subsequent (t2) cTnI values (ng/L) in patients subdivided by ED discharge diagnosis.
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ED Diagnosis group
N of patients (%)
cTnI t1
median (IQR),
N of patients (%)
cTnI t2
median (IQR),
N of patients (%)





POS at both times: 34 (61.8)





POS at both times: 27 (33.3)





POS at both times: 22 (36.7)
IQR - interquartile range; COPD - chronic obstructive pulmonary disease; TIA - transient ischemic attack; CNS - central nervous 
system. 
In each cell, median and IQR of cTnI at t1 and at t2 (first raw) are reported together with the absolute frequency and percentage 
of cTnI positivity (second raw). Percentages of cTnI positivity at each time are calculated within each “discharge diagnosis” group 
(second column) 
*: P < 0.01 vs. all other groups
cTnI, coronary angiography and ECG
The 303 patients discharged from ED with ACS 
(STEMI or NSTEMI) were admitted to cardiology 
department for further examinations. 250 out of 
303 (83%) underwent coronary angiography, 
whereas the remaining 53 (18%) were considered 
at highest risk for the procedure. Conversely, 135 
patients without STEMI or NSTEMI were subjected 
to coronary angiography, most of them having 
persistent chest pain (85) or acute cardiac failure 
(21). Stenosis over 50% lumen diameter of 1 or 
more coronary arteries was present in 225/250 
(90%) patients with ACS, 62/85 (73%) patients with 
persistent chest pain and 9/12 (43%) patients with 
acute cardiac failure, respectively. Patients with 
stenosis > 50% lumen diameter of 1 or more coro-
nary arteries showed significantly higher cTnI val-
ues both at time 1 and 2 than patients with lower 
degree of arterial obstruction (P < 0.001). 
ECG data were available in 1,404 patients. At ad-
mission, 455 patients (32.4%) displayed no ECG al-
terations, 262 (18.7%) and 203 (14.4%) showed ECG 
changes suggestive of ACS or atrial fibrillation, 
while 484 (34.5%) showed other ECG changes. Pa-
tients without ECG changes displayed significantly 
lower cTnI values at both times than all other 
groups (Bonferroni correction: P<0.003). Converse-
ly, patients with ECG changes suggestive of ACS 
showed significantly higher cTnI values at both 
times than all other groups (Bonferroni correction: 
P < 0.003).
cTnI, co-morbidities or history of cardiac 
disease
Patients with hypertension and/or diabetes and/or 
renal insufficiency displayed basal and following 
cTnI values significantly higher than patients with-
out comorbidities (P < 0.001). Accordingly, patients 
with 1 or more comorbidities showed cTnI concen-
trations (P < 0.001) significantly higher than pa-
tients without comorbidities.
Patients with positive cardiac history (any type) 
displayed cTnI values at both times significantly 
higher than patients who did not report any previ-
ous cardiac disease (P < 0.001).
Predictive power of cTnI to detect 
“unequivocal ACS”
In the whole sample population, cTnI positivity 
showed sensitivity and specificity of 74% and 62% 
for basal cTnI, and 94% and 57% for subsequent 
cTnI, respectively (Table 2). Although the negative 
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predictive value (NPV) was found to be high at 
both time points (98% t1 and 99% t2), the positive 
predictive value (PPV) appeared overall modest 
(10% t1 and 11% t2). cTnI performance was also in-
vestigated in different subgroups of patients: 
those with chest pain, in the subgroup with ECG 
changes related to ACS, as well as in the subgroup 
with both chest pain and ECG changes related to 
ACS (Table 2). A progressive increase of diagnostic 
performance was hence observed in parallel with 
the presence of clinical signs and ECG findings 
suggestive of MI.
Predictors of cTnI positivity at time 1
In the cohort of patients (N = 3,166), age, absence 
of chest pain, presence of hypertension, diabetes 
or renal insufficiency, elevated HR (> 100 bpm), 
presence of ECG changes were significantly associ-
ated with basal cTnI positivity in univariate analy-
sis. However, only age, elevated HR and presence 
of ECG changes remained independently associat-
ed with cTnI positivity at admission in multivariate 
analysis (Table 3).
Group Se (%) Sp (%) PPV (%) NPV (%)
cTnI positivity (time 1)
Whole population 74 (66-82) 62 (60-64) 10 (8-12) 98 (97-98)
Patients with chest pain 74 (66-82) 77 (73-80) 41 (34-47) 93 (91-95)
Patients with ECG changes related to ACS 74 (66-82) 42 (32-54) 65 (57-73) 53 (41-65)
Patients with chest pain AND ECG changes related to ACS 74 (66-82) 56 (23-85) 96 (89-99) 14 (5-30)
cTnI positivity (time 2)
Whole population 94 (87-97) 57 (55-59) 11 (9-13) 99 (98-100)
Patients with chest pain 94 (87-97) 71 (67-74) 41 (35-47) 98 (96-99)
Patients with ECG changes related to ACS 94 (87-97) 35 (25-46) 68 (60-75) 79 (62-90)
Patients with chest pain AND ECG changes related to ACS 94 (87-97) 44 (15-77) 96 (90-98) 33 (11-65)
Values are expressed as percentages and 95% confidence interval.
Table 2. Sensitivity (Se), specificity (Sp), predictive positive (PPV) and negative values (NPV) of cTnI to detect “unequivocal ACS”.
Univariate Multivariate
Predictor P OR (95%CI) P OR (95%CI)
Age, years <0.001 1.054 (1.048-1.060)* <0.001 1.032 (1.023-1.042)*
Gender (M vs. F) 0.304 0.925 (0.798-1.073)
Chest pain (YES vs. NO) <0.001 0.424 (0.364-0.494)* 0.754 0.961 (0.748-1.234)
Hypertension (YES vs. NO) <0.001 1.352 (1.165-1.569)* 0.738 1.043 (0.814-1.338)
Diabetes (YES vs. NO) 0.005 1.317 (1.088-1.594)* 0.174 1.241 (0.909-1.693)
Renal insufficiency 















ECG changes (YES vs. NO) <0.001 3.570 (2.733-4.664)* <0.001 2.557 (1.916-3.413)*
OR – odds ratio; CI - confidence interval. 
*: significant predictors
Table 3. Univariate and multivariate analysis of the predictors of cTnI positivity at admission in the whole population investigated. 
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Discussion
As predictable, patients with a diagnosis of ACS in 
the ED displayed median cTnI values significantly 
higher than other groups of diagnosis. Moreover, 
as previously described, significantly higher medi-
an cTnI level was also observed in patients with in-
fections (14). A large number of patients with other 
conditions displayed cTnI positivity, and this evi-
dence is attributable to the fact that the patient 
population presenting to the ED is different from 
the normal population used to establish the diag-
nostics specification of cTnI (15), wherein an in-
creased rate of cTnI positivity may be caused by 
minimal myocardial injury that is typically lacking 
in the reference population. In our study popula-
tion (median age 72 years), a relative 5% increased 
risk of positivity to cTnI was observed for any one-
unit age increase. The remarkable rate of increased 
values observed in the elderly are probably due to 
higher prevalence of left ventricular strain, im-
paired sub-endocardial perfusion, inflammation 
or other undetermined factors, which lead to myo-
cardial injury or cellular myocyte membrane leak-
age (16,17). As regards non-ACS causes of in-
creased values of cTnI in elderly, these findings 
pose a considerable diagnostic problem due to 
the frequent presence of ECG abnormalities (LBBB, 
cardiac device induced rhythm, chronic ischemic 
ECG findings, etc.) that challenge the rule out pro-
cess or the diagnosis of MI. The evidence that age 
is an independent predictor of cTnI positivity 
emerged from our and other studies (16-18) sug-
gests that the adoption of age-specific cTnI cutoffs 
may be regarded as a potentially useful approach 
for increasing the specificity of this test.
It has been reported that up to 100% of patients 
with stable chronic heart failure and CAD have de-
tectable levels of cTnT when measured with a HS 
assay (19). HS-TnT was also detectable in approxi-
mately 25% of adults in the general population 
(17). Interestingly, detectable HS-TnT levels were 
also found to be associated with diabetes, hyper-
tension, impaired renal function, increased left 
ventricular mass, wall thickness and heart cham-
ber dilation. Although similar associations were 
observed in our study in univariate analysis, these 
variables were not independently associated with 
cTnI values in multivariate analysis. Despite in-
creased levels of cTns are frequently encountered 
in subjects with progressive decline of renal func-
tion (20-21), whether the adjustment of cTnI values 
for renal function could be a viable approach for 
increasing its diagnostic specificity, still remains to 
be elucidated, since our multivariate model does 
not support these data.
Supraventricular tachycardia has been associated 
with a troponin elevation without severe CAD (22). 
An increase of high-sensitivity cTn levels has also 
been observed after strenuous exercise (23). We 
demonstrated that positivity for cTnI was indepen-
dently associated with heart rates. More specifical-
ly, compared to patients with HR < 60 bpm, we 
found that those with heart rate between 60 and 
100 bpm or > 100 bpm had a 1.5 and 2.6 higher 
risk of having increased cTnI levels, respectively. 
Since elderly patients have increased ACS-attribut-
able morbidity and mortality, the presence of 
signs and symptoms other than chest pain or 
dyspnea may justify cTnI testing (24). Nevertheless, 
if considering the large number of patients (1,629 
or 51.5%) admitted to the ED without chest pain 
but with serial cTnI measurements, it is conceiva-
ble that at least some of cTn tests were inappropri-
ately and unnecessary requested. In our popula-
tion, 1,537 (49%) patients presented to the ED with 
chest pain but only 230 (15%) were diagnosed as 
having ACS. Conversely, up to 73 out of 303 pa-
tients with an ACS diagnosis (24%) did not report 
chest pain. As such, it is not surprising that the 
presence of chest pain was found to be inversely 
associated (Risk < 1) with cTnI positivity in univari-
ate but not in multivariate analysis (Table 3). 
Despite in our study population cTnI positivity ex-
hibited sensitivity and specificity of 74% and 62% 
(for basal cTnI) and 94% and 57% (for subsequent 
cTnI assay); the PPV at both times was very modest 
(10% at time 1 and 11% at time 2, respectively). 
This is probably attributable to the low prevalence 
of “unequivocal ACS” in our cohort of patients. 
Therefore, we could confirm that the cTnI positivi-
ty should not be straightforwardly considered as 
indicative of ACS in the ED setting, where the prev-
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alence of ACS is typically low. Given the very high 
NPV (98% at t1 and 99% at t2 in the whole popula-
tion), ED physician should hence preferably use a 
cTnI test to exclude ACS diagnosis in this popula-
tion of patients. It is also noteworthy that the PPV 
of cTnI increased substantially in patients with 
higher probability of myocardial ischemia, reach-
ing 96% in those reporting chest pain and show-
ing ECG changes suggestive of ACS. In agreement 
with previous evidence, our results confirm that 
cTnI assay exhibits better performance in two ex-
tremes of patient population, and it should hence 
be used to rule out ACS in patient with low pre-
test probability and confirm this diagnosis in pa-
tient with high pre-test probability (25,26).
We can hence conclude that the diagnostic accu-
racy of HS cTnI assays can be considerably im-
proved when used in patients with a high clinical 
suspicion for MI. Nevertheless, these methods dis-
play lower specificity and increased rate of false 
positive diagnoses of MI, particularly in subjects 
with a low likelihood of MI, with older age, elevat-
ed heart rate or ECG changes. Current guidelines 
recommend more intensive treatment for patients 
with suspected ACS who also display increased 
cTn levels (27). Therefore, the indiscriminate use of 
HS assays without integrating clinical reasoning 
and new approaches to stratify patients with sus-
pected acute MI is likely to expose some patients 
to unnecessary clinical risk and unjustified expens-
es for the health care system.
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